Real-time Estimate Cboe BZX 11:07:51 2024-03-28 am EDT 5-day change 1st Jan Change
0.42 USD -2.33% Intraday chart for Cybin Inc. +4.12% +3.49%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Cybin Inc. announced that it has received $150 million in funding from a group of investors CI
Sector Update: Health Care Stocks Softer Friday Afternoon MT
Cybin Starts Phase 2 Proof-of-Concept Study in Generalized Anxiety Disorder MT
Cybin Inc. Initiates Phase 2 Proof-Of-Concept Study of Cyb004 in Generalized Anxiety Disorder CI
Cybin Reaches Alignment With FDA on Late-Stage Design For Major Depressive Disorder Trial MT
Cybin Inc. Announces Positive End-Of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design CI
Sector Update: Health Care Stocks Ease Wednesday Afternoon MT
Cybin Says Depression Drug Granted Breakthrough Designation by FDA; Raises $150 Million in Private Placement; Shares Jump MT
Transcript : Cybin Inc. - Special Call
Cybin Inc. Receives FDA Breakthrough Therapy Designation for Its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder CI
Cybin Inc. announced that it expects to receive $150 million in funding CI
Cybin Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Cybin Gets FDA Clearance for Generalized Anxiety Disorder Study MT
Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder CI
Cybin Inc. Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028 CI
Cybin Inc. Announces Recent Positive Phase 2 CYB003 Topline Results in MDD and Outlines Key Upcoming Milestones Across its Clinical Development Programs CI
Cybin Inc. Announces the Presentation of Four Posters At the American College of Neuropsychopharmacology Annual Meeting CI
Transcript : Cybin Inc. - Special Call
Cybin Inc. Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses CI
HC Wainwright Adjusts Cybin Price Target to $5 From $10, Maintains Buy Rating MT
Cybin Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Transcript : Cybin Inc. - Special Call
Cybin Inc. Provides Update on its Clinical-Stage Programs and Key Upcoming Milestones Across its Development Pipeline CI
Cybin Inc. Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose CI
Small Pharma Brief: Cybin Completed Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics MT
Chart Cybin Inc.
More charts
Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N,N-dimethyltryptamine (DMT) and dDMT programs creates a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II. It has an intellectual property portfolio in the psychedelic drug development sector with over 30 patents granted and 160 patents pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands and Ireland.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.5844 CAD
Average target price
6.568 CAD
Spread / Average Target
+1,023.89%
Consensus
  1. Stock
  2. Equities
  3. Stock Cybin Inc. - Nyse
  4. News Cybin Inc.
  5. Cybin to Buy Clinical Trial From Entheon Biomedical to Advance Development of CYB004